Daiichi Sankyo continues to advance its pipeline, offering positive catalysts over the next year. Click here to read why ...

AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about ...

Daiichi Sankyo has emerged victorious in appeals court, flipping a prior multimillion-dollar patent verdict on its head and ...

A U.S. appeals court on Tuesday overturned a nearly $42 million jury verdict won by Pfizer's Seagen against Japanese rival ...

If you are wondering whether Daiichi Sankyo Company is starting to look like a bargain or still has room to fall, you are not alone; this stock has quietly shifted from market favorite to value ...

Daiichi Sankyo’s Dr Michael Zaiac discusses how AI, biomarkers and targeted therapies are shaping oncology’s future.

Daiichi Sankyo Company ( ($JP:4568) ) has provided an announcement. The U.S. Federal Circuit Court of Appeals has vacated a previous infringement ...

On December 2, the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit) reversed a decision from the U.S.

In the January 2025 presentation, Jazz Pharmaceuticals expects zanidatamab to potentially receive approval and be launched as ...

Daiichi Sankyo showcases strength of industry-leading ADC portfolio with latest research updates from five landmark breast cancer trials at SABCS: Tokyo Tuesday, December 9, 2025, ...

Nearly 580 participants will be enrolled at sites across Europe, Asia, South America, and North America.

Japan’s stock market is witnessing a record wave of large private transactions known as block trades, stemming from companies ...